FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3169657890> ?p ?o ?g. }

• W3169657890 endingPage "S582" @default.
• W3169657890 startingPage "S581" @default.
• W3169657890 abstract "Abstract Background In a previous abstract (ECCO 2014), we showed geographical differences between European countries in the use of 5ASA suppositories. The updated ECCO guidelines published in 2016 reiterated the importance of mesalazine suppositories in patients with ulcerative colitis: A mesalamine 1-g suppository once daily is the preferred initial treatment for mild or moderately active proctitis, mesalamine foam or enemas are an alternative, but suppositories deliver the drug more effectively to the rectum and are better tolerated [Statement 11A]. We wanted to look at the changes in mesalazine suppositories use and compare it to 2012. Methods We collected the data of suppositories consumption from April 2019 until March 2020 from IMS, the prevalence of UC in 2019 from the Global Health Data Exchange and the estimation of the population for 15 European countries (Czech Republic, Denmark, Estonia, Finland, France, Greece, Germany, Ireland, Latvia, Lithuania, Norway, Portugal, Spain, Sweden and the United Kingdom) from the Eurostat database. For comparison purposes, we assumed that all the patients could receive a 1000 mg daily dose of mesalazine suppository. Results The aggregate sales data from IMS show that 26979 kg of mesalazine suppository were consumed during the full year in 15 European countries. If we exclude Spain from the analysis, 23096 kg were consumed by 14 countries and this is a 1.6-fold increase in comparison to 2012. Assuming a cut-off of 33% of UC patients receiving the maximum daily dose of 1000 mg, 4 countries showed high use of mesalazine suppositories above that cut off: Greece, Ireland, Spain and Portugal. Except for Ireland, those 3 other countries are from Southern Europe. In addition when we compare the data from 2019 to 2012, we see a clear increase in the use of mesalazine suppository in the 14 countries. All countries showed an increase in suppository use that is above 50% except for Czech Republic, Denmark, France and Sweden. The increase in those countries was less pronounced. Sweden and Norway had the lowest rate of suppository use compared to the other countries. Conclusion Despite all the uncertainty around the UC prevalence and parallel import (due to price difference between the different European countries), there is a clear trend toward a higher use of suppositories in all the European countries. A full analysis of the topical use of mesalazine (suppository, foam and enema) would be interesting to evaluate more accurately the adherence to the ECCO guidelines in clinical practice." @default.
• W3169657890 created "2021-06-22" @default.
• W3169657890 creator A5047611161 @default.
• W3169657890 creator A5069318729 @default.
• W3169657890 creator A5069696904 @default.
• W3169657890 date "2021-05-01" @default.
• W3169657890 modified "2023-10-16" @default.
• W3169657890 title "P650 A trend to higher adoption of mesalazine suppository use for UC patients in 15 European countries" @default.
• W3169657890 doi "https://doi.org/10.1093/ecco-jcc/jjab076.770" @default.
• W3169657890 hasPublicationYear "2021" @default.
• W3169657890 type Work @default.
• W3169657890 sameAs 3169657890 @default.
• W3169657890 citedByCount "0" @default.
• W3169657890 crossrefType "journal-article" @default.
• W3169657890 hasAuthorship W3169657890A5047611161 @default.
• W3169657890 hasAuthorship W3169657890A5069318729 @default.
• W3169657890 hasAuthorship W3169657890A5069696904 @default.
• W3169657890 hasBestOaLocation W31696578901 @default.
• W3169657890 hasConcept C126322002 @default.
• W3169657890 hasConcept C2778042862 @default.
• W3169657890 hasConcept C2779134260 @default.
• W3169657890 hasConcept C2779174533 @default.
• W3169657890 hasConcept C2780479503 @default.
• W3169657890 hasConcept C2908647359 @default.
• W3169657890 hasConcept C71924100 @default.
• W3169657890 hasConcept C98274493 @default.
• W3169657890 hasConcept C99454951 @default.
• W3169657890 hasConceptScore W3169657890C126322002 @default.
• W3169657890 hasConceptScore W3169657890C2778042862 @default.
• W3169657890 hasConceptScore W3169657890C2779134260 @default.
• W3169657890 hasConceptScore W3169657890C2779174533 @default.
• W3169657890 hasConceptScore W3169657890C2780479503 @default.
• W3169657890 hasConceptScore W3169657890C2908647359 @default.
• W3169657890 hasConceptScore W3169657890C71924100 @default.
• W3169657890 hasConceptScore W3169657890C98274493 @default.
• W3169657890 hasConceptScore W3169657890C99454951 @default.
• W3169657890 hasIssue "Supplement_1" @default.
• W3169657890 hasLocation W31696578901 @default.
• W3169657890 hasOpenAccess W3169657890 @default.
• W3169657890 hasPrimaryLocation W31696578901 @default.
• W3169657890 hasRelatedWork W185958559 @default.
• W3169657890 hasRelatedWork W2363928628 @default.
• W3169657890 hasRelatedWork W2369093569 @default.
• W3169657890 hasRelatedWork W2369794931 @default.
• W3169657890 hasRelatedWork W2386554890 @default.
• W3169657890 hasRelatedWork W2412874898 @default.
• W3169657890 hasRelatedWork W2789604115 @default.
• W3169657890 hasRelatedWork W2885263273 @default.
• W3169657890 hasRelatedWork W2899944076 @default.
• W3169657890 hasRelatedWork W3166489939 @default.
• W3169657890 hasVolume "15" @default.
• W3169657890 isParatext "false" @default.
• W3169657890 isRetracted "false" @default.
• W3169657890 magId "3169657890" @default.
• W3169657890 workType "article" @default.